The duo plan to establish a global center of excellence in theranostics, taking advantage of Siemens’ state-of-the-art technology and software to advance the use of radiopharmaceuticals in cancer care.
The Impella CP heart pump is being used more and more to treat cardiogenic shock, and the benefits are clear. For many older patients, however, the technology seem to fall short.
Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."
Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.
There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes.